Fostemsavir

(Rukobia®)

Rukobia®

Drug updated on 11/15/2023

Dosage FormTablet (oral: 600 mg)
Drug ClassHuman immunodeficiency virus type 1 gp120-directed attachment inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

Product Monograph / Prescribing Information

Document TitleYearSource
Rukobia (fostemsavir) Prescribing Information.2022ViiV Healthcare, Research Triangle Park, NC

Randomized Controlled Trials